Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors
Hothorn M, Wachter A, Gromes R, Stuwe T, Rausch T, Scheffzek K (septiembre de 2006)
Murata, H
GLOW is a three-peptide blend combining BPC-157, TB-500, and GHK-Cu in a single 70mg lyophilized vial
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
When people talk about microdosing GLP-1s, theyre basically describing a DIY approach to these medsusing less than the manufacturers recommended dose or not injecting as often